WebAug 25, 2024 · Merck has announced that its phase 2 INTR@PID BTC 055 study evaluating bintrafusp alfa with gemcitabine plus cisplatin in the first-line treatment of patients with … WebJul 26, 2024 · In August 2024, the phase II/III INTR@PID BTC 055 trial (NCT04066491) was announced to be discontinued based on a review of the data conducted by the …

Merck Statement on Phase II Study of Bintrafusp Alfa in First-Line ...

WebMerck KGaA, Darmstadt, Germany has decided to discontinue the phase 2 INTR@PID BTC 055 trial examining bintrafusp alfa plus gemcitabine and cisplatin in the frontline … WebAug 24, 2024 · Merck KGaA announced it has decided to discontinue the Phase II INTR@PID BTC 055 study evaluating bintrafusp alfa with gemcitabine plus cisplatin in … companies in hp19

Merck KGaA’s dual immuno-oncology weapon misfires Evaluate

WebAug 24, 2024 · Merck KGaA discontinues its P-II INTR@PID BTC 055 study evaluating bintrafusp alfa with gemcitabine + cisplatin in patients with locally advanced or metastatic BTC The discontinuation is based on the IDMC’s recommendation following a review of data which concluded that the trial fails to meet the primary objective of OS & no new safety … WebJan 21, 2024 · Sellside consensus for 2026 sales was a restrained $504m, according to EvaluatePharma. In a statement yesterday, Merck said trials in more obscure cancer types, and in combination NSCLC settings, were continuing. But there is no denying that the front-line monotherapy failure knocks a big hole in its immuno-oncology strategy. WebMar 16, 2024 · Not intended for UK-based media DARMSTADT, Germany, March 16, 2024 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced topline data from the ... companies in hutchinson mn